MNG1200
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.625
- INTERFERON_GAMMA_RESPONSE+0.539
- OXIDATIVE_PHOSPHORYLATION+0.528
- MYC_TARGETS_V1+0.526
- PROTEIN_SECRETION+0.466
- E2F_TARGETS+0.461
- G2M_CHECKPOINT+0.441
- MTORC1_SIGNALING+0.426
- ADIPOGENESIS+0.421
- MYC_TARGETS_V2+0.417
Top 10 suppressed
- KRAS_SIGNALING_DN-0.275
- MYOGENESIS-0.137
- PANCREAS_BETA_CELLS-0.134
- HEDGEHOG_SIGNALING-0.108
- ANGIOGENESIS-0.105
- APICAL_SURFACE-0.066
- COAGULATION-0.049
- TNFA_SIGNALING_VIA_NFKB-0.041
- WNT_BETA_CATENIN_SIGNALING-0.025
- P53_PATHWAY-0.006
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG485 | — | — | 0.909 |
| 2 | E97A62A3-E4D3-435C-9165-C0075358578E | — | — | 0.903 |
| 3 | C14BEAAE-A766-4ADE-A9B4-674D8717591F | — | — | 0.902 |
| 4 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.902 |
| 5 | BS_RD4D5F9F | Med | Medulloblastoma | 0.895 |
| 6 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.889 |
| 7 | D9385661-DBBA-4AF7-B7E6-857BF84CF7CD | — | — | 0.888 |
| 8 | F42071CA-8794-4C79-8B02-8D48C70E8BA1 | — | — | 0.887 |
| 9 | SRR934931 | — | — | 0.886 |
| 10 | BS_2EN3X6HB | high-grade glioma | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.625 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.539 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.528 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.526 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.466 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.461 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.441 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.426 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.421 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.417 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.401 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.393 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.386 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.351 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.327 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.322 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.312 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.303 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.292 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |